Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts

Clinical and Vaccine Immunology

Volumn 15, Issue 8, 2008, Pages 1145-1150

  Hui, George ^a   Choe, Dan ^a   Hashimoto, Caryn ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; B7 ANTIGEN; CD86 ANTIGEN; DRUG CARRIER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MEROZOITE SURFACE PROTEIN 1; PHOSPHORYL LIPID A; PROTEIN ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; DRUG EFFICACY; DRUG FORMULATION; EMULSION; IMMUNIZATION; IMMUNOGENETICS; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; EMULSIONS; IMMUNIZATION; LIPID A; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMODIUM FALCIPARUM;

EID: 49149118834     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00058-08     Document Type: Article

References (44)

1. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424:329-334.
2. Angov, E., E. S. Bergman-Leitner, E. H. Duncan, A. Brent-Kirk, M. McCasland, R. Mease, L. Soisson, M.-A. Demoitie, B. R. Ogutu, D. G. Heppner, and J. A. Lyon. 2007. Measurement of antibody fine specificities induced by malaria vaccine FMP1/ASO2A from a pediatric phase 2B trial in western Kenya. Am. J. Trop. Med. Hyg., vol. 77, issue 5 (Suppl.), abstr. 12.
3. Brady, C. P., R. L. Shimp, A. P. Miles, M. Whitmore, and A. W. Stowers. 2001. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris. Protein Expr. Purif. 23:468-475.
4. Chang, S. P., S. E. Case, W. L. Gosnell, A. Hashimoto, K. J. Kramer, L. Q. Tam, C. Q. Hashiro, C. M. Nikaido, H. L. Gibson, C. T. Lee-Ng, P. J. Barr, B. T. Yokota, and G. S. Hut. 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64:253-261.
5. Chang, S. P., H. L. Gibson, C. T. Lee-Ng, P. J. Barr, and G. S. Hui. 1992. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J. Immunol. 149:548-555.
6. Chang, S. P., C. M. Nikaido, A. C. Hashimoto, C. Q. Hashiro, B. T. Yokota, and G. S. Hui. 1994. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype. J. Immunol. 152:3483-3490.
7. Chen, X., J. He, and L. J. Chang. 2004. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 1:37.
8. Fischer, H. G., R. Dorfler, B. Schade, and U. Hadding. 1999. Differential CD86/B7-2 expression and cytokine secretion induced by Toxoplasma gondii in macrophages from resistant or susceptible BALB H-2 congenic mice. Int. Immunol. 11:341-349.
9. Gordon, D. M., T. W. McGovern, U. Krzych, J. C. Cohen, I. Schneider, R. LaChance, D. G. Heppner, G. Yuan, M. Hollingdale, M. Slaoui, et al. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1576-1585.
10. Gupta, S., H. Vohra, B. Saha, C. K. Nain, and N. K. Ganguly. 1996. Macrophage-T cell interaction in murine salmonellosis: selective down-regulation of ICAM-1 and B7 molecules in infected macrophages and its probable role in cell-mediated immunity. Eur. J. Immunol. 26:563-570.
11. Hui, G., and C. Hashimoto. 2007. Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Vaccine 25:6598-6603.
12. Hui, G., and C. Hashimoto. 2007. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine 25:948-956.
13. Hui, G., and C. Hashimoto. 2007. The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Vaccine 25:8549-8556.
14. Hui, G. S., and S. P. Chang. 1992. Plasmodium falciparum: induction of biologically active antibodies to gp195 is dependent on the choice of adjuvants. Exp. Parasitol. 75:155-157.
15. Hui, G. S., S. P. Chang, H. Gibson, A. Hashimoto, C. Hashiro, P. J. Barr, and S. Kotani. 1991. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. J. Immunol. 147:3935-3941.
16. Hui, G. S., and C. N. Hashimoto. 2008. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int. Immunopharmacol. 8:1012-1022.
17. Hui, G. S., and W. A. Siddiqui. 1987. Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro. Exp. Parasitol. 64: 519-522.
18. Hui, G. S., L. Q. Tam, S. P. Chang, S. E. Case, C. Hashiro, W. A. Siddiqui, T. Shiba, S. Kusumoto, and S. Kotani. 1991. Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. Infect. Immun. 59:1585-1591.
19. Hunter, R. L. 2002. Overview of vaccine adjuvants: present and future. Vaccine 20(Suppl. 3):S7-S12.
20. Ismaili, J., J. Rennesson, E. Aksoy, J. Vekemans, B. Vincart, Z. Amraoui, F. Van Laethem, M. Goldman, and P. M. Dubois. 2002. Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol. 168:926-932.
21. Johnson, D. A., D. S. Keegan, C. G. Sowell, M. T. Livesay, C. L. Johnson, L. M. Taubner, A. Harris, K. R. Myers, J. D. Thompson, G. L. Gustafson, M. J. Rhodes, J. T. Ulrich, J. R. Ward, Y. M. Yorgensen, J. L. Cantrell, and V. G. Brookshire. 1999. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem. 42:4640-4649.
22. Kaye, P. M., N. J. Rogers, A. J. Curry, and J. C. Scott. 1994. Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur. J. Immunol. 24:2850-2854.
23. Kotani, S. 1992. Bacterial cell surface biological response modifiers and their synthetic counterparts. Adv. Exp. Med. Biol. 319:145-164.
24. Lambert, H., N. Hitziger, I. Dellacasa, M. Svensson, and A. Barragan. 2006. Induction of dendritic cell migration upon Toxoplasma gondii infection potentiates parasite dissemination. Cell. Microbiol. 8:1611-1623.
25. Lambros, C., and J. P. Vanderberg. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420.
26. Mencacci, A., E. Cenci, G. Del Sero, C. Fè d'Ostiani, P. Mosci, C. Montagnoli, A. Bacci, F. Bistoni, V. F. Quesniaux, B. Ryffel, and L. Romani. 1998. Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int. Immunol. 10:37-48.
27. Miller, L. H., T. Roberts, M. Shahabuddin, and T. F. McCutchan. 1993. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. 59:1-14.
28. Mitchell, T. C., D. Hildeman, R. M. Kedl, T. K. Teague, B. C. Schaefer, J. White, Y. Zhu, J. Kappler, and P. Marrack. 2001. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat. Immunol. 2:397-402.
29. Morgan, W. D., B. Birdsall, T. A. Frenkiel, M. G. Gradwell, P. A. Burghaus, S. E. Syed, C. Uthaipibull, A. A. Holder, and J. Feeney. 1999. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J. Mol. Biol. 289:113-122.
30. Morgan, W. D., T. A. Frenkiel, M. J. Lock, M. Grainger, and A. A. Holder. 2005. Precise epitope mapping of malaria parasite inhibitory antibodies by TROSY NMR cross-saturation. Biochemistry 44:518-523.
31. Morgan, W. D., M. J. Lock, T. A. Frenkiel, M. Grainger, and A. A. Holder. 2004. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR. Mol. Biochem. Parasitol. 138:29-36.
32. Ockenhouse, C. F., E. Angov, K. E. Kester, C. Diggs, L. Soisson, J. F. Cummings, A. V. Stewart, D. R. Palmer, B. Mahajan, U. Krzych, N. Tornieporth, M. Delchambre, M. Vanhandenhove, O. Ofori-Anyinam, J. Cohen, J. A. Lyon, and D. G. Heppner. 2006. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24:3009-3017.
33. O'Hagan, D. T., and N. M. Valiante. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2:727-735.
34. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:S63-S68.
35. Petrovsky, N., and J. C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82:488-496.
36. Planelles, L., M. C. Thomas, C. Maranon, M. Morell, and M. C. Lopez. 2003. Differential CD86 and CD40 co-stimulatory molecules and cytokine expression pattern induced by Trypanosoma cruzi in APCs from resistant or susceptible mice. Clin. Exp. Immunol. 131:41-47.
37. Polhemus, M. E., A. J. Magill, J. F. Cummings, K. E. Kester, C. F. Ockenhouse, D. E. Lanar, S. Dutta, A. Barbosa, L. Soisson, C. L. Diggs, S. A. Robinson, J. D. Haynes, V. A. Stewart, L. A. Ware, C. Brando, U. Krzych, R. A. Bowden, J. D. Cohen, M. C. Dubois, O. Ofori-Anyinam, E. De Kock, W. R. Ballou, and D. G. Heppner, Jr. 2007. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25:4203-4212.
38. Rawlings, D. J., and D. C. Kaslow. 1992. Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens. J. Exp. Med. 176:1483-1487.
39. Rickman, L. S., D. M. Gordon, R. Wistar, Jr., U. Krzych, M. Gross, M. R. Hollingdale, J. E. Egan, J. D. Chulay, and S. L. Hoffman. 1991. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 337: 998-1001.
40. Rosa, D. S., L. K. Iwai, F. Tzelepis, D. Y. Bargieri, M. A. Medeiros, I. S. Soares, J. Sidney, A. Sette, J. Kalil, L. E. Mello, E. Cunha-Neto, and M. M. Rodrigues. 2006. Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect. 8:2130-2137.
41. Singh, M., and D. T. O'Hagan. 2002. Recent advances in vaccine adjuvants. Pharm. Res. 19:715-728.
42. Singh, S., K. Miura, H. Zhou, O. Muratova, B. Keegan, A. Miles, L. B. Martin, A. J. Saul, L. H. Miller, and C. A. Long. 2006. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74:4573-4580.
43. Thompson, B. S., P. M. Chilton, J. R. Ward, J. T. Evans, and T. C. Mitchell. 2005. The low-toxicity versions of LPS, MPL(R) adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 78:1273-1280.
44. Ubol, S., B. Aiamkitsumrit, S. Nitayaphan, S. Sirinavin, and S. Kitthawee. 2004. Detection of the impairment of CD80 expression on circulating monocytes in HIV-infected Thai children. Microbiol. Immunol. 48:557-560.